Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 2
1990 2
1991 2
1992 4
1993 6
1994 25
1995 41
1996 54
1997 96
1998 96
1999 113
2000 120
2001 142
2002 148
2003 154
2004 211
2005 191
2006 228
2007 225
2008 248
2009 264
2010 251
2011 245
2012 242
2013 241
2014 233
2015 256
2016 253
2017 214
2018 236
2019 236
2020 231
2021 194
Text availability
Article attribute
Article type
Publication date

Search Results

4,675 results
Results by year
Filters applied: . Clear all
Page 1
Venlafaxine.
Singh D, Saadabadi A. Singh D, et al. 2021 Aug 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 Aug 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 30570984 Free Books & Documents. Review.
Venlafaxine is FDA approved to treat and manage symptoms of depression, social anxiety disorder, and cataplexy. ...Venlafaxine may be used independently or as part of combination therapy with other drugs. ...
Venlafaxine is FDA approved to treat and manage symptoms of depression, social anxiety disorder, and cataplexy. ...Venlafaxine
Venlafaxine: more dangerous than most "selective" serotonergic antidepressants.
[No authors listed] [No authors listed] Prescrire Int. 2016 Apr;25(170):96-9. Prescrire Int. 2016. PMID: 27186622 Review.
Large British and Danish cohort studies found no increased risk of sudden cardiac death with venlafaxine compared with other antidepressants. However, since only 3.5% and 7% of the patients were using venlafaxine, the statistical power of these studies was relativel …
Large British and Danish cohort studies found no increased risk of sudden cardiac death with venlafaxine compared with other antidepr …
Venlafaxine pharmacogenetics: a comprehensive review.
Suwała J, Machowska M, Wiela-Hojeńska A. Suwała J, et al. Pharmacogenomics. 2019 Jul;20(11):829-845. doi: 10.2217/pgs-2019-0031. Epub 2019 Aug 1. Pharmacogenomics. 2019. PMID: 31368838 Review.
Antidepressant response could be from 42 to 50% genetically determined. Venlafaxine (VEN) was the sixth most-prescribed antidepressant in the USA in 2017. ...
Antidepressant response could be from 42 to 50% genetically determined. Venlafaxine (VEN) was the sixth most-prescribed antidepressan …
Venlafaxine.
[No authors listed] [No authors listed] 2021 Feb 15. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. 2021 Feb 15. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. PMID: 30000251 Free Books & Documents. Review.
Infants receive venlafaxine and its active metabolite in breastmilk, and the metabolite of the drug can be found in the plasma of most breastfed infants; however, concurrent side effects have rarely been reported. ...However, newborn infants of mothers who took the drug du …
Infants receive venlafaxine and its active metabolite in breastmilk, and the metabolite of the drug can be found in the plasma of mos …
Venlafaxine Therapy and CYP2D6 Genotype.
Dean L. Dean L. 2015 Jul 27 [updated 2020 Jun 29]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. 2015 Jul 27 [updated 2020 Jun 29]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 28520361 Free Books & Documents. Review.
As such, individuals that have high plasma concentrations of venlafaxine and low plasma concentrations of ODV when taking venlafaxine, indicates they have reduced or absent CYP2D6 activity. ...The label states that although imipramine (an antidepressant that inhibit …
As such, individuals that have high plasma concentrations of venlafaxine and low plasma concentrations of ODV when taking venlafax
Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review.
Aiyer R, Barkin RL, Bhatia A. Aiyer R, et al. Pain Med. 2017 Oct 1;18(10):1999-2012. doi: 10.1093/pm/pnw261. Pain Med. 2017. PMID: 27837032 Review.
METHODS: Literature was reviewed on MEDLINE using various key words. These key words include: "venlafaxine and pain," "venlafaxine ER and pain," "venlafaxine XR and pain," "venlafaxine and neuropathic pain," "venlafaxine and neuropathy," "SSRI a …
METHODS: Literature was reviewed on MEDLINE using various key words. These key words include: "venlafaxine and pain," "venlafaxine
Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy.
Farshchian N, Alavi A, Heydarheydari S, Moradian N. Farshchian N, et al. Cancer Chemother Pharmacol. 2018 Nov;82(5):787-793. doi: 10.1007/s00280-018-3664-y. Epub 2018 Aug 13. Cancer Chemother Pharmacol. 2018. PMID: 30105459 Clinical Trial.

RESULTS: Grade of cranial, motor, sensory and neuropathic pain decreased significantly in venlafaxine and duloxetine groups. This reduction was more considerable in duloxetine group compared to venlafaxine group (P < 0.05). ...Duloxetine was more effective than

RESULTS: Grade of cranial, motor, sensory and neuropathic pain decreased significantly in venlafaxine and duloxetine groups. This red …
A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder.
Fagiolini A, Albert U, Ferrando L, Herman E, Muntean C, Pálová E, Cattaneo A, Comandini A, Di Dato G, Di Loreto G, Olivieri L, Salvatori E, Tongiani S, Kasper S. Fagiolini A, et al. Int Clin Psychopharmacol. 2020 May;35(3):137-146. doi: 10.1097/YIC.0000000000000304. Int Clin Psychopharmacol. 2020. PMID: 31972628 Free PMC article. Clinical Trial.
This double-blind, randomized study evaluated the efficacy and safety of trazodone OAD (once-a-day) in comparison with venlafaxine XR (extended-release) in 324 patients (166 trazodone and 158 venlafaxine) with major depressive disorder (MDD). ...Both treatments were …
This double-blind, randomized study evaluated the efficacy and safety of trazodone OAD (once-a-day) in comparison with venlafaxine XR …
First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review.
Lassen D, Ennis ZN, Damkier P. Lassen D, et al. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):32-6. doi: 10.1111/bcpt.12497. Epub 2015 Nov 3. Basic Clin Pharmacol Toxicol. 2016. PMID: 26435496 Free article. Review.
Following the PRISMA guideline for systematic reviews, we performed a systematic search on the risk of major congenital malformations after first trimester in utero exposure to venlafaxine or duloxetine. We identified eight cohort studies reporting on the outcome upon in u …
Following the PRISMA guideline for systematic reviews, we performed a systematic search on the risk of major congenital malformations after …
Venlafaxine-induced encephalopathy in term newborn.
Maalouli WM, Hilliard BS. Maalouli WM, et al. SAGE Open Med Case Rep. 2020 Aug 27;8:2050313X20952981. doi: 10.1177/2050313X20952981. eCollection 2020. SAGE Open Med Case Rep. 2020. PMID: 32922797 Free PMC article.
The use of venlafaxine, a selective serotonin and norepinephrine reuptake inhibitor, for the management of depression in women of childbearing age has been on the rise, and there have been multiple case reports in the literature tying venlafaxine in-utero exposure t …
The use of venlafaxine, a selective serotonin and norepinephrine reuptake inhibitor, for the management of depression in women of chi …
4,675 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page